Besivance (Besifloxacin Ophthalmic Suspension) Drug Information: Side Effects and Drug Interactions

Pill Identifier Search

May 25, 2012

Besivance

Sty (Stye) »

What is a sty?

A sty (sometimes spelled stye) is a tender, painful red bump located at the base of an eyelash or under or inside the eyelid. A sty results from a localized infection of the glands or a hair follicle of the eyelid. The medical term for a sty is hordeolum (plural, hordeola).

The term external hordeolum refers to a sty that develops at the base of an eyelash (the hair follicle), whereas the term internal hordeolum refers to a sty that develops in a meibomian gland, a gland located on the underside of the eyelid that secretes an oily substance onto the eyeball.

A sty is sometimes confused with a chalazion (see below), which is a cyst or a specific type of scarring due to chronic inflammation arising in the meibomian glands of the eyelid. A chalazion may develop when the infection of a sty persists over time, resulting in scarring around the meibomian gland. In contrast to a sty, a chalazion is usually painless. ...

Read the Sty (Stye) article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Besivance User Reviews >>

Besivance

Eye Diseases and Conditions Slideshow Pictures

Pink Eye Slideshow Pictures

Cataracts Slideshow Pictures

font size

SIDE EFFECTS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice. The data described below reflect exposure to Besivance™ (besifloxacin ophthalmic suspension) in approximately 1,000 patients between 1 and 98 years old with clinical signs and symptoms of bacterial conjunctivitis. The most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients.

Other adverse events reported in patients receiving Besivance™ (besifloxacin ophthalmic suspension) occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.